Makers Laboratories Ltd is Rated Hold

Rating Context and Current Position

On 04 August 2026, Makers Laboratories Ltd’s rating was revised from 'Sell' to 'Hold' by MarketsMOJO, accompanied by a significant improvement in its Mojo Score, which rose from 47 to 60 points. This shift indicates a more balanced outlook on the stock, suggesting that while it may not be a strong buy, it is no longer considered a sell. Investors should note that this rating change reflects a reassessment of the company’s prospects based on a combination of factors, but the detailed financial and market data presented here are current as of 01 October 2026.

Quality Assessment: Below Average Fundamentals

As of 01 October 2026, Makers Laboratories Ltd exhibits below average quality metrics. The company’s long-term fundamental strength remains modest, with an average Return on Capital Employed (ROCE) of 8.06%. This figure suggests that the company generates moderate returns on its invested capital, which is below the levels typically favoured by growth-oriented investors. Furthermore, the company’s net sales have grown at an annualised rate of 6.39% over the past five years, while operating profit has increased at a slightly higher rate of 13.27%. These growth rates indicate steady but unspectacular expansion, reflecting a cautious growth trajectory within the Pharmaceuticals & Biotechnology sector.

Valuation: Fair but Discounted

Currently, Makers Laboratories Ltd is valued fairly relative to its peers, with a Price to Book Value ratio of approximately 1.5. This valuation suggests the stock is trading at a modest discount compared to the average historical valuations of similar companies in the sector. The company’s Return on Equity (ROE) stands at 3.2%, which is relatively low, indicating limited profitability relative to shareholder equity. Despite this, the stock’s valuation appears reasonable given its market capitalisation as a microcap and the sector dynamics. Investors seeking value may find this pricing attractive, especially considering the company’s recent performance.

Financial Trend: Very Positive Momentum

The latest data as of 01 October 2026 shows a very positive financial trend for Makers Laboratories Ltd. The company has reported a net profit growth of 29.21%, with positive results declared for three consecutive quarters, signalling improving operational efficiency and profitability. Notably, the Profit Before Tax excluding other income (PBT LESS OI) for the most recent quarter reached ₹5.68 crores, representing a remarkable growth rate of 140.9% compared to the previous four-quarter average. Additionally, the company’s debtors turnover ratio for the half-year period is at a high of 7.08 times, indicating efficient management of receivables. Net sales for the latest quarter also hit a record high of ₹42.77 crores, underscoring robust demand and revenue generation.

Technical Outlook: Bullish Sentiment

From a technical perspective, Makers Laboratories Ltd is currently exhibiting a bullish trend. The stock has delivered strong returns over multiple time frames, including a 1-day gain of 1.11%, a 3-month increase of 25.80%, and a 6-month rise of 19.92%. Year-to-date, the stock has surged by 58.70%, and over the past year, it has generated a commendable return of 37.36%. This performance notably outpaces the BSE500 index over the last one year, three years, and three months, highlighting the stock’s market-beating momentum. Such technical strength often reflects positive investor sentiment and can be a favourable indicator for medium-term price appreciation.

Balancing Strengths and Weaknesses

While Makers Laboratories Ltd shows encouraging financial trends and technical strength, investors should be mindful of its below average quality metrics and modest valuation multiples. The company’s long-term growth rates and profitability ratios suggest that it is not yet a high-growth or high-return stock, which may temper expectations for aggressive capital appreciation. However, the recent improvements in profitability and operational efficiency, combined with a reasonable valuation and bullish technical signals, justify the current 'Hold' rating. This rating implies that investors may consider maintaining their positions but should await further fundamental improvements before increasing exposure.

Shareholding and Market Position

The majority shareholding of Makers Laboratories Ltd remains with its promoters, which can provide stability in corporate governance and strategic direction. As a microcap entity within the Pharmaceuticals & Biotechnology sector, the company operates in a competitive environment but has demonstrated resilience and the ability to generate market-beating returns in recent periods. This positioning supports a cautious but optimistic outlook for the stock.

What the Hold Rating Means for Investors

For investors, the 'Hold' rating on Makers Laboratories Ltd suggests a neutral stance. It indicates that the stock is fairly valued given its current fundamentals and market conditions, and that there is neither a compelling reason to buy aggressively nor to sell immediately. Investors holding the stock may choose to maintain their positions while monitoring upcoming quarterly results and sector developments for signs of sustained improvement or deterioration. New investors might consider waiting for clearer signals of fundamental strength or a more attractive valuation before initiating positions.

Summary of Key Metrics as of 01 October 2026

The company’s Mojo Score stands at 60.0, reflecting a balanced assessment across quality, valuation, financial trend, and technical parameters. The quality grade remains below average, valuation is fair, financial trend is very positive, and technical grade is bullish. Stock returns have been robust, with a 37.36% gain over the past year and a 58.70% increase year-to-date. Despite these gains, profitability metrics such as ROE and ROCE remain modest, underscoring the need for cautious optimism.

Conclusion

Makers Laboratories Ltd’s current 'Hold' rating by MarketsMOJO, last updated on 04 August 2026, reflects a nuanced view of the company’s prospects. While the stock benefits from strong recent financial performance and positive technical momentum, its fundamental quality and valuation metrics suggest measured expectations. Investors should consider this rating as an indication to maintain current holdings and watch for further developments that could influence the stock’s trajectory in the Pharmaceuticals & Biotechnology sector.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today